Physician profile
William Rath
NPI 1154377406
$1,070.60
in general payments reported to CMS, 2019-2025
16 companies · $22.49 in 2025
The $22.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $522 · 2021: $148 · 2022: $166 · 2023: $14.10 · 2024: $42.24 · 2025: $22.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.02 | 2021-2025 | |
| Novo Nordisk INC | $215.74 | 2019-2021 | |
| Amgen INC. | $107.89 | 2019-2020 | |
| Amarin Pharma, INC. | $97.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $92.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $50.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.58 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.35 | 2019 | |
| Pfizer INC. | $25.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.02 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.97 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.75 | 2020 | |
| Assertio Therapeutics, INC. | $14.06 | 2020 | |
| Glaxosmithkline, LLC. | $13.52 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.